Gevers TJG - Search Results

1

The effect of disease severity markers on quality of life in autosomal dominant polycystic kidney disease: a systematic review, meta-analysis and meta-regression.

Neijenhuis MK, Kievit W, Perrone RD, Sloan JA, Erwin P, Murad MH, Gevers TJG, Hogan MC, Drenth JPH. Neijenhuis MK, et al. Among authors: gevers tjg. BMC Nephrol. 2017 May 25;18(1):169. doi: 10.1186/s12882-017-0578-6. BMC Nephrol. 2017. PMID: 28545401 Free PMC article. Review.

2

Improved outcomes after hypothermic oxygenated machine perfusion in liver transplantation-Long-term follow-up of a multicenter randomized controlled trial.

Czigany Z, Uluk D, Pavicevic S, Lurje I, Froněk J, Keller T, Strnad P, Jiang D, Gevers T, Koliogiannis D, Guba M, Tolba RH, Meister FA, Neumann UP, Kocik M, Kysela M, Sauer IM, Raschzok N, Schöning W, Popescu I, Tacke F, Pratschke J, Lurje G. Czigany Z, et al. Hepatol Commun. 2024 Feb 3;8(2):e0376. doi: 10.1097/HC9.0000000000000376. eCollection 2024 Feb 1. Hepatol Commun. 2024. PMID: 38315126 Free PMC article. Clinical Trial.

3

Somatostatin analogues for treatment of polycystic liver disease.

Gevers TJ, Drenth JP. Gevers TJ, et al. Curr Opin Gastroenterol. 2011 May;27(3):294-300. doi: 10.1097/MOG.0b013e328343433f. Curr Opin Gastroenterol. 2011. PMID: 21191289 Review.

4

Treatment extension benefits HCV genotype 1 patients without rapid virological response: a systematic review.

Gevers TJ, Slavenburg S, van Oijen MG, Drenth JP. Gevers TJ, et al. Neth J Med. 2011 May;69(5):216-21. Neth J Med. 2011. PMID: 21646668 Free article. Review.

5

Hepatic and renal manifestations in autosomal dominant polycystic kidney disease: a dichotomy of two ends of a spectrum.

van Gulick JJ, Gevers TJ, van Keimpema L, Drenth JP. van Gulick JJ, et al. Neth J Med. 2011 Sep;69(9):367-71. Neth J Med. 2011. PMID: 21978978 Free article. Review.

6

Low prevalence of cardiac valve abnormalities in patients with autosomal dominant polycystic liver disease.

Gevers TJ, de Koning DB, van Dijk AP, Drenth JP. Gevers TJ, et al. Liver Int. 2012 Apr;32(4):690-2. doi: 10.1111/j.1478-3231.2011.02683.x. Epub 2011 Nov 14. Liver Int. 2012. PMID: 22099398 No abstract available.

7

The long-term outcome of patients with polycystic liver disease treated with lanreotide.

Chrispijn M, Nevens F, Gevers TJ, Vanslembrouck R, van Oijen MG, Coudyzer W, Hoffmann AL, Dekker HM, de Man RA, van Keimpema L, Drenth JP. Chrispijn M, et al. Aliment Pharmacol Ther. 2012 Jan;35(2):266-74. doi: 10.1111/j.1365-2036.2011.04923.x. Epub 2011 Nov 24. Aliment Pharmacol Ther. 2012. PMID: 22111942 Free article. Clinical Trial.

8

Rationale and design of the RESOLVE trial: lanreotide as a volume reducing treatment for polycystic livers in patients with autosomal dominant polycystic kidney disease.

Gevers TJ, Chrispijn M, Wetzels JF, Drenth JP. Gevers TJ, et al. BMC Nephrol. 2012 Apr 4;13:17. doi: 10.1186/1471-2369-13-17. BMC Nephrol. 2012. PMID: 22475206 Free PMC article. Clinical Trial.

9

Diagnosis and management of polycystic liver disease.

Gevers TJ, Drenth JP. Gevers TJ, et al. Nat Rev Gastroenterol Hepatol. 2013 Feb;10(2):101-8. doi: 10.1038/nrgastro.2012.254. Epub 2013 Jan 8. Nat Rev Gastroenterol Hepatol. 2013. PMID: 23296249 Review.

10

Everolimus does not further reduce polycystic liver volume when added to long acting octreotide: results from a randomized controlled trial.

Chrispijn M, Gevers TJ, Hol JC, Monshouwer R, Dekker HM, Drenth JP. Chrispijn M, et al. J Hepatol. 2013 Jul;59(1):153-9. doi: 10.1016/j.jhep.2013.03.004. Epub 2013 Mar 14. J Hepatol. 2013. PMID: 23499726 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

80 results

Search Page